Stocktoria
Prelude Therapeutics Inc PRLD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-09-25
Prelude Therapeutics Inc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -861.3% | -1995.9% | — | — | — |
| Net margin | -819.6% | -1816.8% | — | — | — |
| FCF margin | -464.3% | -1480.7% | — | — | — |
| Return on assets | -70.4% | -72.5% | -43.9% | -52.4% | -36.6% |
| Return on equity | -145.0% | -96.7% | -51.4% | -59.1% | -39.1% |
| Current ratio | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 |
| Revenue growth | 73.4% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001678660 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.